From: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Clinical trial | Phase | α-PD-1/PD-L1 | Targeted therapy (Target) | Cancer type | Primary outcome measures |
---|---|---|---|---|---|
NCT01454102 | 1 | Nivolumab | Erlotinib (EGFR) | NSCLC | Safety |
NCT02013219 | 1 | Atezolizumab | Erlotinib (EGFR) | NSCLC | Safety, RP2D |
NCT02143466 | 1 | Durvalumab | Osimertinib (EGFR) | NSCLC | Safety |
NCT02454933 | 3 | Durvalumab | Osimertinib (EGFR) | NSCLC | Safety |
NCT02574078 | 1/2 | Nivolumab | Crizotinib (Met/ALK/ROS) | NSCLC | Safety |
NCT02511184 | 1 | Pembrolizumab | Crizotinib (Met/ALK/ROS) | NSCLC | Safety |
NCT02013219 | 1 | Atezolizumab | Alectinib (ALK/ FLT3/RET) | NSCLC | Safety, RP2D |
NCT02584634 | 2 | Avelumab | Crizotinib (Met/ALK/ROS) | NSCLC | ORR, Safety |
NCT02660034 | 1 | Tislelizumab | Pamiparib (PARP) | Solid tumor | Safety, ORR, PFS, DOR, DCR, CBR, OS |
NCT04475939 | 3 | Pembrolizumab | Niraparib (PARP) | NSCLC | PFS, OS |
NCT02657889 | 1/2 | Pembrolizumab | Niraparib (PARP) | TNBC, Ovarian cancer | Safety, ORR |
NCT02734004 | 2 | Durvalumab | Olaparib (PARP) | Ovarian cancer | DCR, ORR, Safety |
NCT02484404 | 1/2 | Durvalumab | Olaparib (PARP) | Solid tumor | RP2D, ORR |
NCT01988896 | 1 | Atezolizumab | Cobimetinib (MEK) | Solid tumor | Safety, RP2D |
NCT02322814 | 2 | Atezolizumab | Cobimetinib (MEK) | TNBC | PFS, ORR |
NCT02788279 | 3 | Atezolizumab | Cobimetinib (MEK) | Colorectal cancer | OS |
NCT03600883 | 1/2 | Unspecified | AMG 510 (KRAS) | KRAS p.G12C mutant solid tumor | Safety |
NCT02972034 | 1 | Pembrolizumab | MK-8353 (ERK) | Solid tumor | Safety |
NCT02967692 | 3 | PDR001 | Dabrafenib (RAF) and Trametinib (MEK) | Melanoma | Safety, PFS |
NCT04017650 | 1/2 | Nivolumab | Encorafenib (RAF) and Cetuximab (EGFR) | Colorectal cancer | Best radiographic response; Safety |
NCT03502733 | 1 | Nivolumab | Copanlisib (PI3K) | Solid tumor and lymphoma | Safety |
NCT03395899 | 2 | Atezolizumab | Ipatasertib (AKT) | Breast cancer | 2-fold increase in GzmB+CD8+ T cell |
NCT02393248 | 1/2 | Pembrolizumab | Pemigatinib (FGFR) | Solid tumor | Maximum tolerated dose, Pharmacodynamics |
NCT03123055 | 1/2 | Pembrolizumab | B-701 (FGFR) | Urothelial cell carcinoma | Safety, ORR |
NCT02819596 | 2 | Durvalumab | Savolitinib (c-MET) | Renal cell carcinoma | Safety, ORR |
NCT02779751 | 1 | Pembrolizumab | Abemaciclib (CDK4/6) | NSCLC, Breast cancer | Safety |
NCT04000529 | 1 | Spartalizumab | TNO155 (SHP-2) | Solid tumor | Safety |